BLADDER • Mercurrey Hospital, Thane
Bladder Cancer in Thane — Mercurrey Hospital
Medically reviewed by Mr. Harshawardhan Godbole, MS, MCh, FRCS.Ed, DNB(Urol), FRCS(Urol)
Last medically reviewed: 21 May 2026
Last updated: 21 May 2026
The Ghodbunder Road corridor's corporate and professional population — IT workers, managers, executives in their 40s and 50s — includes individuals whose occupational histories, lifestyle factors, and health screening habits create a specific bladder cancer risk profile. Corporate health screenings increasingly include urine dipstick testing, and microscopic haematuria found on these screenings requires specialist follow-up that many corporate health departments do not facilitate. Mercurrey Hospital at Kapurbawdi junction provides the specialist bladder cancer assessment that Ghodbunder Road's health-aware professional community needs: cystoscopy, upper tract imaging, and where needed, TURBT and BCG therapy — all available at a location 10–15 minutes from most Ghodbunder Road residential communities.
Bladder cancer most commonly presents as transitional cell carcinoma (TCC). Non-muscle-invasive bladder cancer (NMIBC) — Stages Ta, T1, CIS — is managed with TURBT (transurethral resection), intravesical BCG or chemotherapy, and flexible cystoscopy surveillance. Muscle-invasive bladder cancer (MIBC — T2+) requires radical cystectomy (laparoscopic where possible) or radical radiotherapy. Any episode of haematuria (blood in urine) in an adult requires urgent cystoscopy and upper tract imaging to exclude bladder cancer regardless of other possible explanations. Smoking is the most significant modifiable risk factor.
### Corporate Health Screening Microscopic Haematuria — What to Do Next
Urine dipstick at corporate health screenings frequently detects microscopic haematuria (blood in the urine detectable only on chemical testing, not visible to the naked eye). Many corporate health providers note this finding without a clear follow-up pathway. Microscopic haematuria in a symptomatic adult, or in a high-risk individual (over 40, smoker, occupational exposure), requires specialist assessment. At Mercurrey Hospital, Mr. Godbole's team evaluates microscopic haematuria in the full clinical context — determining whether flexible cystoscopy and CT urography are indicated or whether the finding is likely to be benign (medication-related, strenuous exercise-related, or from a urological condition other than cancer).
### Upper Tract Urothelial Cancer — An Under-Recognised Risk in Thane
Bladder cancer and upper tract urothelial cancer (UTUC) — cancers of the renal pelvis and ureter — share the same carcinogens and risk factors. A proportion of patients who present with haematuria at Mercurrey Hospital have an upper tract source rather than a bladder source for their bleeding. CT urography — which images the entire urothelial tract from kidney to bladder — is essential for identifying upper tract tumours that flexible cystoscopy alone would miss. Mr. Godbole's haematuria investigation protocol at Mercurrey Hospital includes CT urography alongside cystoscopy for this reason.
### Travel and Parking Guide – Mercurrey Hospital, Kapurbawdi
High Street Mall Junction, Samata Nagar, Kapurbawdi, Majiwada 400607. From Hiranandani Estate: 10–12 minutes via Ghodbunder Road. From Manpada: 15 minutes. From Brahmand: 20 minutes. Auto-rickshaws know the junction as "Kapurbawdi High Street Mall." Street parking available.
Why choose Mercurrey Hospital for bladder cancer?
- Ghodbunder Road professionals choose Mercurrey Hospital because the Kapurbawdi location is 10–20 minutes from their homes — making the cystoscopy, CT imaging, and follow-up appointments that bladder cancer investigation requires practically manageable around demanding work schedules.
- Mr. Godbole's haematuria investigation protocol at this location includes CT urography to exclude upper tract urothelial cancer — an investigation that many general urology services in Thane do not perform routinely alongside cystoscopy.
- Microscopic haematuria found on corporate health screening receives specialist contextual assessment at Mercurrey Hospital — determining whether full investigation is indicated, rather than leaving patients with an unexplained finding and no follow-up plan.
Bladder Cancer cost at Mercurrey Hospital
Consultation fee: ₹1,000 at Mercurrey Hospital. Treatment costs vary — call +91 88280 71522 for a detailed estimate. [INTERNAL LINK → /fees/]
Risk Factors for Bladder Cancer
The list is not exhaustive but some factors leading to bladder cancer are shown below:
- Smoking
- Chronic bladder irritation
- Parasitic infections
- Exposure to certain types of chemicals such as aniline dyes
- Occupational hazard such as in industrial printing inks
Symptoms of bladder cancer
- Bladder cancer needs to be excluded in any patient who presents with haematuria (blood in the urine)
- Increased frequency of urination or urgency may also herald bladder cancer
- Advanced stages can present with symptoms relevant to the spread of the disease
Treatment for Bladder Cancer
Treatment for bladder cancer depends on whether the cancer is limited to the urothelium or invaded into the structure (wall) of the bladder. Treatment hence ranges from endoscopic (camera based) resections +/- intravesical therapy (chemotherapy into the bladder) right to neoadjuvant chemotherapy with radical surgery or radiotherapy. A multidisciplinary approach is essential for successful long-term outcomes for such cancers.
Coming in for your bladder cancer appointment
Mercurrey Hospital serves bladder cancer patients from Majiwada, Kapurbawdi, Ghodbunder Road, Manpada, Hiranandani Estate, Brahmand, Owale, Kolshet, and Pokhran Road. Patients from Mira Road and Bhayander also attend this clinic as the closest Cancer Lead urology option.
Patient reviews — bladder cancer at Mercurrey Hospital
Amandeep Sodhi
Ghodbunder Road
My corporate health check showed microscopic haematuria. My company doctor suggested it was probably dehydration. I came to Mercurrey Hospital for specialist assessment. CT urography identified a small upper tract urothelial tumour in the left ureter — a finding that cystoscopy alone would have completely missed. Treatment was arranged promptly. The CT urography as a routine part of the haematuria investigation was what found a cancer that would otherwise have been missed.
March 2026
Meena Bhatt
Hiranandani Estate
My husband had visible haematuria twice. His company doctor prescribed antibiotics. At Mercurrey Hospital, cystoscopy was done within 3 days. A papillary bladder tumour was found. TURBT performed. Low-grade Ta cancer — excellent prognosis with surveillance. The speed from haematuria to diagnosis to treatment at Mercurrey Hospital was the key factor. Surveillance cystoscopy at 3 months: clear. BCG not needed for this grade.
February 2026
Naresh Bhandari
Manpada
I had haematuria investigated at a clinic near Manpada that found nothing on ultrasound. Coming to Mercurrey Hospital for cystoscopy showed a small flat lesion — CIS. The invisible-on-imaging CIS that required cystoscopy to find was the cancer that had been causing my symptoms. BCG therapy started immediately. Surveillance cystoscopy at 3 months showed complete response. The cystoscopy investigation that the ultrasound-only clinic had not performed found the cancer.
January 2026
Lalitha Krishnamurthy
Brahmand
I came from Brahmand to Mercurrey Hospital for bladder cancer follow-up after my initial TURBT was performed elsewhere. Mr. Godbole's team took over the BCG therapy and surveillance cystoscopy programme seamlessly. The structured follow-up — cystoscopy at 3 months, 6 months, and annually — gives me confidence that my bladder is being monitored appropriately. Having the same specialist team doing every surveillance cystoscopy provides consistency that I value.
March 2026
Pawan Khatri
Kapurbawdi
Living near Kapurbawdi junction made Mercurrey Hospital the obvious practical choice for my bladder cancer surveillance cystoscopies. What I appreciate most is that each cystoscopy is done by a Cancer Lead specialist — not a trainee — which means any early recurrence is caught by the most experienced eyes. Three surveillance cystoscopies so far, all clear. The specialist continuity at this location is what I chose it for.
February 2026
Frequently asked questions
My corporate health check urine test showed 'blood in urine' — is this bladder cancer?
Microscopic haematuria on a dipstick test is not specific to bladder cancer — it can be caused by UTI, kidney stones, vigorous exercise, BPH, or anticoagulant medications. However, in a symptomatic adult over 40 or a high-risk individual, it requires specialist assessment to exclude bladder and kidney cancer. Mr. Godbole's team at Mercurrey Hospital evaluates microscopic haematuria in full clinical context — determining whether cystoscopy and CT urography are indicated for your specific risk profile.
What is CT urography and why is it done alongside cystoscopy for haematuria?
CT urography is a CT scan with IV contrast specifically optimised to image the entire urothelial tract — kidneys, ureters, and bladder. It identifies upper tract tumours (renal pelvis and ureteral cancers) that would be missed by cystoscopy, as cystoscopy only visualises the bladder interior. The combination of flexible cystoscopy (bladder) and CT urography (upper tract) provides a complete haematuria investigation covering all potential urothelial cancer sites.
I work in IT — does my occupation affect my bladder cancer risk?
Standard office-based IT work does not carry elevated bladder cancer risk. However, if your work has involved exposure to industrial chemicals — aromatic amines in printing, dye, leather, or rubber manufacturing — this does carry elevated risk. Additionally, the sedentary working pattern common in IT roles increases the time urine sits in the bladder, theoretically increasing carcinogen contact time, though this is a minor factor compared to smoking. The most significant action any IT professional can take to reduce bladder cancer risk is smoking cessation.
Is bladder cancer curable if treated early at Mercurrey Hospital?
Yes. Non-muscle-invasive bladder cancer (Stage Ta and T1) treated with complete TURBT followed by BCG therapy has an excellent long-term prognosis. Low-grade Ta cancer has a very low risk of progression to muscle-invasive disease; high-grade T1 cancer with BCG maintenance therapy has progression rates of 10–20% over 5 years with appropriate management. Stage 1 bladder cancer does not require bladder removal — it is managed with cystoscopic surveillance and intravesical therapy.
How does BCG therapy work and is it available at Mercurrey Hospital?
BCG (Bacillus Calmette-Guérin) is instilled directly into the bladder through a urinary catheter and left for 1–2 hours before voiding. The immune response it triggers attacks remaining tumour cells and creates an immune memory that reduces recurrence. BCG is given once weekly for 6 weeks (induction) and then as maintenance therapy (3 weekly instillations at 3, 6, 12, 18, 24, 30, and 36 months for intermediate and high-risk NMIBC). BCG therapy is coordinated by HRG Urology at Mercurrey Hospital as part of the complete bladder cancer management pathway.
Risk Factors for Bladder Cancer
The list is not exhaustive but some factors leading to bladder cancer are shown below: Smoking Chronic bladder irritation Parasitic infections Exposure to certain types of chemicals such as aniline dyes Occupational hazard such as in industrial printing inks
Symptoms of bladder cancer
Bladder cancer needs to be excluded in any patient who presents with haematuria (blood in the urine) Increased frequency of urination or urgency may also herald bladder cancer Advanced stages can present with symptoms relevant to the spread of the disease
Treatment for Bladder Cancer
Treatment for bladder cancer depends on whether the cancer is limited to the urothelium or invaded into the structure (wall) of the bladder. Treatment hence ranges from endoscopic (camera based) resections +/- intravesical therapy (chemotherapy into the bladder) right to neoadjuvant chemotherapy with radical surgery or radiotherapy. A multidisciplinary approach is essential for successful long-term outcomes for such cancers.